NielsRHolm Profile Banner
Niels R. Holm Profile
Niels R. Holm

@NielsRHolm

Followers
2K
Following
3K
Statuses
1K

MD and trialist. PCI vs CABG. PCI techniques, OCT imaging, imaging based physiology. Enjoy working with the greatest team!

Aarhus Univ. Hospital Denmark
Joined June 2019
Don't wanna be here? Send us removal request.
@NielsRHolm
Niels R. Holm
3 days
RT @mirvatalasnag: @EuroInterventio More from RENOVATE COMPLEX PCI Trial °Higher ARR following IVI-guided PCI w more complex lesions °P…
0
9
0
@NielsRHolm
Niels R. Holm
6 days
RT @mmamas1973: Intravascular imaging is undertaken in 29% of PCI cases in UK 78% of lms cases and 26% of ACS cases This must be one of t…
0
22
0
@NielsRHolm
Niels R. Holm
7 days
RT @EuroInterventio: NEW ISSUE OUT 📌A State-of-the-art on mechanical circulatory support for high-risk PCI; 📌Safety data of revascula…
0
10
0
@NielsRHolm
Niels R. Holm
7 days
@mmamas1973 @sbrugaletta .. and many live cases with imaging have since ended with a 2 sec look at the scan - without identifying the inferior result - and then a physician concluding that this is an acceptable angiographic result
0
0
2
@NielsRHolm
Niels R. Holm
8 days
RT @NielsRHolm: @sbrugaletta Agree. One-stent with kissing also benefits substantially from guiding by IVI
0
1
0
@NielsRHolm
Niels R. Holm
8 days
RT @BakhshiHooman: The last but not least clinical trial : FAVOR III Europe @TCTConference @TCT_ME_ @crfheart @TCTConference @falkindi404
0
3
0
@NielsRHolm
Niels R. Holm
8 days
@sbrugaletta Agree. One-stent with kissing also benefits substantially from guiding by IVI
0
1
5
@NielsRHolm
Niels R. Holm
17 days
RT @DrDerekConnolly: I often see GLP1s stopped in HF but in this study in patients with obesity-related HFpEF T2DM,Semaglutide improved HF…
0
2
0
@NielsRHolm
Niels R. Holm
17 days
RT @SusannBeier: Have you checked out our review article on using 3D printing in cardiovascular applications? Explore the entire process an…
0
1
0
@NielsRHolm
Niels R. Holm
17 days
RT @DrPeterOKane: Important update on 🇬🇧 PCI guidelines now published - first time since 2015 ! Will be presented & discussed @ACI 2025 ne…
0
15
0
@NielsRHolm
Niels R. Holm
17 days
RT @EmilHolckMD: Happy to co-author this paper with @MarLombard1 and @JEscaned 🔥. The outcome of a productive research stay in Madrid !
0
3
0
@NielsRHolm
Niels R. Holm
20 days
@RickVolleberg Impressive. We have a single case with a 10mm repeat but your case is with clear pullback and forward creating 3 repeats… Rare but important ‘artefact’ in lesion length assessment
0
1
3
@NielsRHolm
Niels R. Holm
1 month
Europas tab af konkurrenceevne overfor Kina og USA bør have maksimal politisk fokus. Det er selvskabt, politisk besluttet bureaukrati, der spænder ben for store sektorer, forskning og udvikling @mfMorten @ChristinaEgelun @DanskErhverv @DanskIndustri
0
0
0
@NielsRHolm
Niels R. Holm
1 month
RT @TCTMD: Deferred Revascularization Safer When Guided by FFR vs QFR: FAVOR III Europe
Tweet media one
0
5
0
@NielsRHolm
Niels R. Holm
1 month
RT @PCRonline: Coronary revascularisation deferral based on QFR or FFR: a post-hoc analysis 🔎 of the FAVOR III Europe trial @drgocchipin
0
6
0
@NielsRHolm
Niels R. Holm
1 month
RT @NishithChandra: OCT and IVUS imaging improves PCI results. Indispensable tools for complex PCI. @Hragy
0
5
0
@NielsRHolm
Niels R. Holm
1 month
@flightradar24 VJH521 also diverted
0
0
1
@NielsRHolm
Niels R. Holm
1 month
@TCTMD The new publication is a subanalysis of the defer population in @FAVORIIITrial
0
1
1
@NielsRHolm
Niels R. Holm
1 month
@mirvatalasnag 1) The trial was designed for both CCS and NCL in ACS and at staged proc. No diff (few events in sub-subgroups) 2) Currently evaluating the Cx issue. The magnitude points to a calibration issue 3) Likely - although we did not provided @FAVORIIITrial data to support such claim
1
0
3